Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention

This study has been completed.
Sponsor:
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT00610870
First received: January 27, 2008
Last updated: March 2, 2011
Last verified: March 2011

January 27, 2008
March 2, 2011
July 2007
February 2009   (final data collection date for primary outcome measure)
Myocardial infarct size by SPECT [ Time Frame: between 5 and 14 days after acute myocardial infarction ] [ Designated as safety issue: No ]
Myocardial infarct size by SPECT [ Time Frame: within 14 days after acute myocardial infarction ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00610870 on ClinicalTrials.gov Archive Site
  • Myocardial infarct size measured by contrast-enhanced MRI [ Time Frame: within 14 days after acute myocardial infarction ] [ Designated as safety issue: No ]
  • Myocardial blush grade after the procedure [ Time Frame: immediate after procedure ] [ Designated as safety issue: No ]
  • complete ST resolution [ Time Frame: at 60 minutes after the procedure ] [ Designated as safety issue: No ]
  • major adverse cardiac events related to left ventricular dysfunction (death, new-onset sustained hypotension or heart failure, and hospital readmission for left ventricular dysfunction) [ Time Frame: at 6 months after the procedure ] [ Designated as safety issue: No ]
Myocardial infarct size measured by contrast-enhanced MRI [ Time Frame: within 14 days after acute myocardial infarction ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention
Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

The purpose of this study to determine whether statin pretreatment decrease myocardial infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Angioplasty, Transluminal, Percutaneous Coronary
Drug: atorvastatin
atorvastatin 80mg/day before primary coronary intervention
  • Experimental: 1
    Atorvastatin group
    Intervention: Drug: atorvastatin
  • No Intervention: 2
    Control group
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
173
August 2009
February 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset
  • ST segment elevation more than 1 mm in two or more contiguous leads or presumably a new onset left bundle branch blockage

Exclusion Criteria:

  • Cardiogenic shock
  • History of myocardial infarction
  • Chronic liver disease
  • Previous or current statin use
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT00610870
2007-04-049
No
HC Gwon, MD,PhD / Professor, Samsung Medical Center
Samsung Medical Center
Not Provided
Principal Investigator: Hyeon-Cheol Gwon, MD, PhD Samsung Medical Center
Samsung Medical Center
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP